rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

KALA BIO, Inc.

KALA · Nasdaq

Health CareBiotechnologyNot moving yet

KALA stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 93.6% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$126K
Officials’ trades on record
0
Institutions holding
13 (-9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$851K$0$1.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 2

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders13-9 on the quarter
New · exited4 · 13
Reported value$1.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026220,623$382K+160,074+264.4%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026145,152$251K-115,909−44.4%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026101,396$175K+71,768+242.2%
BlackRock, Inc.added · filed 7 Aug 202671,542$124K+60,733+561.9%
NORTHERN TRUST CORPadded · filed 13 Aug 202641,606$72K+30,082+261.0%
Qube Research & Technologies Ltdnew · filed 14 Aug 202611,073$19K+11,073
GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 202610,921$19K-3,127−22.3%
UBS Group AGreduced · filed 13 Aug 20269,057$16K-57,814−86.5%
Tower Research Capital LLC (TRC)new · filed 11 Aug 2026616$1,066+616
BARCLAYS PLCnew · filed 14 Aug 2026608$1,052+608
31 Mar 2023 – 30 Jun 2026
142128Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

David E. Lazar Company insiderChief Executive Officer · last 18 Dec 20250 · 0
Mark T. Iwicki Company insiderDirector · last 23 Oct 20250 · 14
Mary Reumuth Company insiderCHIEF FINANCIAL OFFICER · last 23 Oct 20250 · 14
Darius Kharabi Company insiderCHIEF BUSINESS OFFICER · last 22 Oct 20250 · 7
Romulus K. Brazzell Company insiderSEE REMARKS · last 22 Oct 20250 · 13
Todd Bazemore Company insiderDirector · last 22 Oct 20253 · 13
Julian Baker Company insiderOther · last 1 Oct 20250 · 2
Andrew I. Koven Company insiderDirector · last 15 Jun 20250 · 0
C. Daniel Myers Company insiderDirector · last 15 Jun 20250 · 0
Gregory D. Perry Company insiderDirector · last 15 Jun 20250 · 0
Howard B. Rosen Company insiderDirector · last 15 Jun 20251 · 0
Marjan Farid Company insiderDirector · last 15 Jun 20250 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2024 · to 31 Dec 2024-106%
Debt to equityFY 2024 · to 31 Dec 20242.47×
Share count trendFY 2024 · to 28 Mar 20255.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.6M

Analyst forecasts

No analyst forecasts yet.